A paper from Marcišauskas et al. reported that ALDOA in cyst fluids and serum can be used as a diagnostic biomarker to separate stage I type 1 and type 2 ovarian cancers from benign serous adenoma (Marcišauskas et al., 2019). This evidence concerns the gene ALDOA and cyst.